Question 1

What is the Meaning of ASPREE Trial?

Accepted Answer

ASPREE (Aspirin in Reducing Events in the Elderly) was a large, randomized, placebo-controlled trial. It investigated whether daily low-dose aspirin prolonged healthy independent living in older adults (70+ years, or 65+ for specific U.S. groups) without pre-existing cardiovascular disease, dementia, or major physical disability. This clarified aspirin's primary prevention role.

Question 2

What is the Context of ASPREE Trial?

Accepted Answer

Operating within geriatric health and cardiovascular primary prevention, this pivotal trial examined antithrombotic therapy in an aging population. It focused on aspirin's systemic effects in healthy older individuals. The study understood aspirin's risk-benefit profile considering physiological changes with aging, influencing cardiovascular risk and bleeding.

Question 3

What is the Significance of ASPREE Trial?

Accepted Answer

ASPREE profoundly influenced clinical guidelines for aspirin use in primary prevention among older adults. It showed low-dose aspirin did not reduce the primary composite endpoint of death, dementia, or persistent physical disability. Increased major hemorrhage risk was demonstrated, altering assumptions, emphasizing individualized clinical assessment.

Question 4

What is the Mechanism of ASPREE Trial?

Accepted Answer

Aspirin primarily inhibits cyclooxygenase (COX) enzymes, especially COX-1, crucial for platelet thromboxane A2 synthesis. This reduces platelet aggregation, hindering blood clot formation. The ASPREE Trial evaluated if this antiplatelet action yielded a net clinical benefit by reducing thrombotic events, quantifying associated bleeding risk.

Question 5

What is the Application of ASPREE Trial?

Accepted Answer

ASPREE outcomes directly inform current clinical practice for aspirin prescribing in older adults. Clinicians advise against initiating low-dose aspirin in healthy individuals aged 70 or older without established cardiovascular disease. Increased bleeding risk without clear net benefit promotes a targeted, risk-stratified approach.

Question 6

What is the Metric of ASPREE Trial?

Accepted Answer

The ASPREE Trial's primary outcome was a composite endpoint of all-cause mortality, incident dementia, or persistent physical disability, assessed via validated scales. Secondary outcomes included cardiovascular events, major hemorrhage, and cancer incidence. Data were systematically collected through regular participant visits and medical record reviews.

Question 7

What is the Risk of ASPREE Trial?

Accepted Answer

ASPREE identified notable risks with daily low-dose aspirin in healthy older adults. A significant increase in major hemorrhage (gastrointestinal, intracranial) was observed. The aspirin cohort experienced a slight rise in all-cause mortality, primarily from cancer-related deaths. These outcomes underscore careful patient selection and shared decision-making.

ASPREE Trial

Meaning

Context

Significance

Mechanism

Application

Metric

Risk

How Do Physiological Testosterone Levels Influence Female Heart Health?

Provided by the clinical team
at 4Ever Young Miami Dadeland

-15% ∞ HRTIO15

Your protocol begins with a conversation.

Visit

Schedule Appointment

About

Med & Wellness

4Ever Young Miami Dadeland

Communication

+1 786-529-6686

Email Us

Opening Hours